Our top pick for
Adicet Bio Inc is a biotechnology business based in the US. Adicet Bio shares (ACET) are listed on the NASDAQ and all prices are listed in US Dollars. Adicet Bio employs 81 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$8.43|
|52-week range||$6.25 - $17.55|
|50-day moving average||$7.69|
|200-day moving average||$10.07|
|Wall St. target price||$28.29|
|Dividend yield||N/A (7.43%)|
|Earnings per share (TTM)||$-2.70|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||5.77%|
|1 month (2021-09-21)||19.57%|
|3 months (2021-07-21)||5.11%|
|6 months (2021-04-21)||-34.04%|
|1 year (2020-10-21)||-35.65%|
|2 years (2019-10-21)||19.24%|
|3 years (2018-10-19)||11.91|
|5 years (2016-10-17)||N/A|
Valuing Adicet Bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adicet Bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Adicet Bio's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.82. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adicet Bio's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$9.3 million|
|Gross profit TTM||$17.9 million|
|Return on assets TTM||-17.11%|
|Return on equity TTM||-41.12%|
|Market capitalisation||$256 million|
TTM: trailing 12 months
There are currently 391,534 Adicet Bio shares held short by investors – that's known as Adicet Bio's "short interest". This figure is 5.2% down from 412,935 last month.
There are a few different ways that this level of interest in shorting Adicet Bio shares can be evaluated.
Adicet Bio's "short interest ratio" (SIR) is the quantity of Adicet Bio shares currently shorted divided by the average quantity of Adicet Bio shares traded daily (recently around 83482.729211087). Adicet Bio's SIR currently stands at 4.69. In other words for every 100,000 Adicet Bio shares traded daily on the market, roughly 4690 shares are currently held short.
However Adicet Bio's short interest can also be evaluated against the total number of Adicet Bio shares, or, against the total number of tradable Adicet Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adicet Bio's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Adicet Bio shares in existence, roughly 10 shares are currently held short) or 0.032% of the tradable shares (for every 100,000 tradable Adicet Bio shares, roughly 32 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adicet Bio.
Find out more about how you can short Adicet Bio stock.
We're not expecting Adicet Bio to pay a dividend over the next 12 months.
Adicet Bio's shares were split on a 1:7 basis on 15 September 2020. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Adicet Bio shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Adicet Bio shares which in turn could have impacted Adicet Bio's share price.
Adicet Bio, Inc. , a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.